|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Margueron R and Reinberg D: The Polycomb
complex PRC2 and its mark in life. Nature. 469:343–349. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Di Croce L and Helin K: Transcriptional
regulation by Polycomb group proteins. Nat Struct Mol Biol.
20:1147–1155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bracken AP, Pasini D, Capra M, Prosperini
E, Colli E and Helin K: EZH2 is downstream of the pRB-E2F pathway,
essential for proliferation and amplified in cancer. EMBO J.
22:5323–5335. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sauvageau M and Sauvageau G: Polycomb
group proteins: Multi-faceted regulators of somatic stem cells and
cancer. Cell Stem Cell. 7:299–313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Croonquist PA and Van Ness B: The polycomb
group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene
that influences myeloma cell growth and the mutant ras phenotype.
Oncogene. 24:6269–6280. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kleer CG, Cao Q, Varambally S, Shen R, Ota
I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chien YC, Liu LC, Ye HY, Wu JY and Yu YL:
EZH2 promotes migration and invasion of triple-negative breast
cancer cells via regulating TIMP2-MMP-2/-9 pathway. Am J Cancer
Res. 8:422–434. 2018.PubMed/NCBI
|
|
12
|
Bachmann IM, Halvorsen OJ, Collett K,
Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP and
Akslen LA: EZH2 expression is associated with high proliferation
rate and aggressive tumor subgroups in cutaneous melanoma and
cancers of the endometrium, prostate, and breast. J Clin Oncol.
24:268–273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zingg D, Debbache J, Peña-Hernández R,
Antunes AT, Schaefer SM, Cheng PF, Zimmerli D, Haeusel J, Calçada
RR, Tuncer E, et al: EZH2-mediated primary cilium deconstruction
drives metastatic melanoma formation. Cancer Cell. 34:69–84.e14.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakagawa M and Kitabayashi I: Oncogenic
roles of enhancer of zeste homolog 1/2 in hematological
malignancies. Cancer Sci. 109:2342–2348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ougolkov AV, Bilim VN and Billadeau DD:
Regulation of pancreatic tumor cell proliferation and
chemoresistance by the histone methyltransferase enhancer of zeste
homologue 2. Clin Cancer Res. 14:6790–6796. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maftouh M, Avan A, Funel N, Paolicchi E,
Vasile E, Pacetti P, Vaccaro V, Faviana P, Campani D, Caponi S, et
al: A polymorphism in the promoter is associated with EZH2
expression but not with outcome in advanced pancreatic cancer
patients. Pharmacogenomics. 15:609–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Verma SK, Tian X, LaFrance LV, Duquenne C,
Suarez DP, Newlander KA, Romeril SP, Burgess JL, Grant SW, Brackley
JA, et al: Identification of potent, selective, cell-active
inhibitors of the histone lysine methyltransferase EZH2. ACS Med
Chem Lett. 3:1091–1096. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Glazer RI, Hartman KD, Knode MC, Richard
MM, Chiang PK, Tseng CK and Marquez VE: 3-Deazaneplanocin: A new
and potent inhibitor of S-adenosylhomocysteine hydrolase and its
effects on human promyelocytic leukemia cell line HL-60. Biochem
Biophys Res Commun. 135:688–694. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Raaphorst FM, Meijer CJ, Fieret E,
Blokzijl T, Mommers E, Buerger H, Packeisen J, Sewalt RA, Otte AP
and van Diest PJ: Poorly differentiated breast carcinoma is
associated with increased expression of the human polycomb group
EZH2 gene. Neoplasia. 5:481–488. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Raman JD, Mongan NP, Tickoo SK, Boorjian
SA, Scherr DS and Gudas LJ: Increased expression of the polycomb
group gene, EZH2, in transitional cell carcinoma of the bladder.
Clin Cancer Res. 11:8570–8576. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sudo T, Utsunomiya T, Mimori K, Nagahara
H, Ogawa K, Inoue H, Wakiyama S, Fujita H, Shirouzu K and Mori M:
Clinicopathological significance of EZH2 mRNA expression in
patients with hepatocellular carcinoma. Br J Cancer. 92:1754–1758.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Y, Xie D, Yin Li W, Man Cheung C, Yao
H, Chan CY, Chan CY, Xu FP, Liu YH, Sung JJ and Kung HF: RNAi
targeting EZH2 inhibits tumor growth and liver metastasis of
pancreatic cancer in vivo. Cancer Lett. 297:109–116. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Matsukawa Y, Semba S, Kato H, Ito A,
Yanagihara K and Yokozaki H: Expression of the enhancer of zeste
homolog 2 is correlated with poor prognosis in human gastric
cancer. Cancer Sci. 97:484–491. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tan J, Yang X, Zhuang L, Jiang X, Chen W,
Lee PL, Karuturi RK, Tan PB, Liu ET and Yu Q: Pharmacologic
disruption of Polycomb-repressive complex 2-mediated gene
repression selectively induces apoptosis in cancer cells. Genes
Dev. 21:1050–1063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hirukawa A, Smith HW, Zuo D, Dufour CR,
Savage P, Bertos N, Johnson RM, Bui T, Bourque G, Basik M, et al:
Targeting EZH2 reactivates a breast cancer subtype-specific
anti-metastatic transcriptional program. Nat Commun. 9:25472018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Ai Z, Chen J, Teng Y and Zhu J:
Enhancer of zeste homolog 2 blockade by RNA interference is
implicated with inhibited proliferation, invasion and promoted
apoptosis in endometrial carcinoma. Oncol Lett. 15:9429–9435.
2018.PubMed/NCBI
|
|
27
|
Jones BA, Varambally S and Arend RC:
Histone methyltransferase EZH2: A therapeutic target for ovarian
cancer. Mol Cancer Ther. 17:591–602. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mohammad F, Weissmann S, Leblanc B, Pandey
DP, Højfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT,
et al: EZH2 is a potential therapeutic target for H3K27M-mutant
pediatric gliomas. Nat Med. 23:483–492. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang W, Xie Q, Zhou X, Yao J, Zhu X, Huang
P, Zhang L, Wei J, Xie H, Zhou L and Zheng S: Mitofusin-2 triggers
mitochondria Ca2+ influx from the endoplasmic reticulum to induce
apoptosis in hepatocellular carcinoma cells. Cancer Lett.
358:47–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu TP, Lo HL, Wei LS, Hsiao HH and Yang
PM: S-Adenosyl-L-methionine-competitive inhibitors of the histone
methyltransferase EZH2 induce autophagy and enhance drug
sensitivity in cancer cells. Anticancer Drugs. 26:139–147. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hsieh YY, Lo HL and Yang PM: EZH2
inhibitors transcriptionally upregulate cytotoxic autophagy and
cytoprotective unfolded protein response in human colorectal cancer
cells. Am J Cancer Res. 6:1661–1680. 2016.PubMed/NCBI
|
|
32
|
Xiong X, Zhang J, Liang W, Cao W, Qin S,
Dai L, Ye D and Liu Z: Fuse-binding protein 1 is a target of the
EZH2 inhibitor GSK343, in osteosarcoma cells. Int J Oncol.
49:623–628. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Klionsky DJ, Abdelmohsen K, Abe A, Abedin
MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD,
Adeli K, et al: Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kabeya Y, Mizushima N, Ueno T, Yamamoto A,
Kirisako T, Noda T, Kominami E, Ohsumi Y and Yoshimori T: LC3, a
mammalian homologue of yeast Apg8p, is localized in autophagosome
membranes after processing. EMBO J. 19:5720–5728. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mizushima N, Noda T, Yoshimori T, Tanaka
Y, Ishii T, George MD, Klionsky DJ, Ohsumi M and Ohsumi Y: A
protein conjugation system essential for autophagy. Nature.
395:395–398. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao GS, Gao ZR, Zhang Q, Tang XF, Lv YF,
Zhang ZS, Zhang Y, Tan QL, Peng DB, Jiang DM and Guo QN: TSSC3
promotes autophagy via inactivating the Src-mediated PI3K/Akt/mTOR
pathway to suppress tumorigenesis and metastasis in osteosarcoma
and predicts a favorable prognosis. J Exp Clin Cancer Res.
37:1882018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mizushima N and Komatsu M: Autophagy:
Renovation of cells and tissues. Cell. 147:728–741. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mizushima N: A brief history of autophagy
from cell biology to physiology and disease. Nat Cell Biol.
20:521–527. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Berry DL and Baehrecke EH: Autophagy
functions in programmed cell death. Autophagy. 4:359–360. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hay N and Sonenberg N: Upstream and
downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim J, Kundu M, Viollet B and Guan KL:
AMPK and mTOR regulate autophagy through direct phosphorylation of
Ulk1. Nat Cell Biol. 13:132–141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wei FZ, Cao Z, Wang X, Wang H, Cai MY, Li
T, Hattori N, Wang D, Du Y, Song B, et al: Epigenetic regulation of
autophagy by the methyltransferase EZH2 through an MTOR-dependent
pathway. Autophagy. 11:2309–2322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jarome TJ, Perez GA, Hauser RM, Hatch KM
and Lubin FD: EZH2 methyltransferase activity controls pten
expression and mTOR signaling during fear memory reconsolidation. J
Neurosci. 38:7635–7648. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Qin L, Wang Z, Tao L and Wang Y: ER stress
negatively regulates AKT/TSC/mTOR pathway to enhance autophagy.
Autophagy. 6:239–247. 2010. View Article : Google Scholar : PubMed/NCBI
|
